Cybin (HELP) Income from Continuing Operations (2020 - 2022)

Cybin's (HELP) quarterly Income from Continuing Operations came in at 4552410.37 in Q2 2022, up 186.82% on a QoQ basis from 5243563.44 in Q1 2021.

Cybin (HELP) Income from Continuing Operations (2020 - 2022) Analysis & Trends

Cybin (HELP) has 3 years of Income from Continuing Operations data on file, last reported at 4552410.37 in Q2 2022.

Quarterly Income from Continuing Operations changed N/A year-over-year to 4552410.37 in Q2 2022, while the trailing twelve-month figure through May 2022 was 162821584.03 (changed N/A YoY) and the FY2026 annual result came in at 147810000.0, down 53.91% from the prior year.
Income from Continuing Operations grew to 4552410.37 in Q2 2022, from 5243563.44 in the prior quarter.
In the past five years, Income from Continuing Operations ranged from a high of 144237601.97 in Q2 2020 to a low of 162128509.13 in Q4 2020.
A 3-year average of 3716796.41 and a median of 1921.84 in 2020 frame the typical range for Income from Continuing Operations.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Income (Continuing) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	1.10 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.30 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	482.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-644.37 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	237.01 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-3,096.02
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	81.49 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	164.49 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-13.27 Mn
10	Cybin	417.29 Mn	417.29 Mn	-	-

Download Data